Precision medicine in aggressive thyroid cancer: Moving beyond multitargeted tyrosine kinase inhibitors

Umair Mahmood; Jochen H. Lorch

doi:10.1002/cncy.22516

Precision medicine in aggressive thyroid cancer: Moving beyond multitargeted tyrosine kinase inhibitors

Umair Mahmood, Jochen H. Lorch

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	8-11
Number of pages	4
Journal	Cancer Cytopathology
Volume	130
Issue number	1
DOIs	https://doi.org/10.1002/cncy.22516
State	Published - Jan 2022

Funding

Jochen H. Lorch reports institutional research support from Novartis, Bayer, Takeda, and BMS and consulting fees from Bayer and Lilly. The other author made no disclosures.

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cncy.22516

Cite this

@article{9f0b94555bf4414f809fabbddb479ede,

title = "Precision medicine in aggressive thyroid cancer: Moving beyond multitargeted tyrosine kinase inhibitors",

author = "Umair Mahmood and Lorch, {Jochen H.}",

note = "Funding Information: Jochen H. Lorch reports institutional research support from Novartis, Bayer, Takeda, and BMS and consulting fees from Bayer and Lilly. The other author made no disclosures.",

year = "2022",

month = jan,

doi = "10.1002/cncy.22516",

language = "English (US)",

volume = "130",

pages = "8--11",

journal = "Cancer Cytopathology",

issn = "1934-662X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Precision medicine in aggressive thyroid cancer

T2 - Moving beyond multitargeted tyrosine kinase inhibitors

AU - Mahmood, Umair

AU - Lorch, Jochen H.

N1 - Funding Information: Jochen H. Lorch reports institutional research support from Novartis, Bayer, Takeda, and BMS and consulting fees from Bayer and Lilly. The other author made no disclosures.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85118887414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118887414&partnerID=8YFLogxK

U2 - 10.1002/cncy.22516

DO - 10.1002/cncy.22516

M3 - Article

C2 - 34748686

AN - SCOPUS:85118887414

SN - 1934-662X

VL - 130

SP - 8

EP - 11

JO - Cancer Cytopathology

JF - Cancer Cytopathology

IS - 1

ER -

Precision medicine in aggressive thyroid cancer: Moving beyond multitargeted tyrosine kinase inhibitors

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this